New article: Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum Versus Chemotherapy Alone as First-Line Treatment in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Reconstruction of Partitioned Survival… https://t.co/fTlpQVguu
906 followers
5,333 followers
RT @FarmaOnco: Cost-Effectiveness Analysis of Pembrolizumab + Pemetrexed & Platinum vs Chemo Alone as First-Line in Metastatic Non-Squamou…
2,695 followers
Cost-Effectiveness Analysis of Pembrolizumab + Pemetrexed & Platinum vs Chemo Alone as First-Line in Metastatic Non-Squamous NSCLC: A Reconstruction of Partitioned Survival Model Based on Time Dependent Pricing Mechanism of Patient Assistance Program
6,533 followers
New research: Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum Versus Chemotherapy Alone as First-Line Treatment in Metastatic Non-Squamous Non–Small Cell Lung Cancer: A Reconstruction of Partitioned Survival Model… https://t.co/zw